As precision medicine continues to evolve, translating biomarker discoveries into reliable clinical applications remains a significant challenge. Advances in multi-omics, pathology, proteomics and artificial intelligence (AI) are creating new opportunities to improve clinical trial design, patient stratification and therapeutic development.
In a recent Oxford Global thought leadership interview, Kirsty MacLean, VP, Head of R&D at Cerba Research, discussed the importance of early assay development, global standardisation and integrating complementary technologies to accelerate biomarker translation.
Building Robust Biomarker Strategies from Discovery to Clinical Development
At Cerba Research, MacLean oversees R&D across multiple specialised testing platforms, including flow cytometry, genomics, histopathology and virology. These capabilities support clinical trials across oncology, haematology, rare diseases, autoimmune conditions and vaccine development.
A central priority is ensuring that assays developed during early research can be standardised and deployed consistently across global clinical trials.
MacLean emphasised that one of the biggest challenges in biomarker translation is establishing sufficient analytical rigour, quality control and operational scalability from the outset.
Developers must consider not only the requirements of Phase I trials but also whether their assays, laboratory infrastructure, instrumentation and logistics can support larger, multinational Phase III studies.
Building these capabilities early can help reduce development risks, avoid costly setbacks and support greater consistency throughout clinical development.
Integrating Multi-Omics and Pathology to Strengthen Clinical Insights
MacLean highlighted the growing importance of moving beyond individual analytical technologies towards integrated, multimodal approaches.
Rather than treating flow cytometry, genomics and histopathology as separate disciplines, clinical development increasingly requires these techniques to work together to provide a more comprehensive understanding of disease biology and treatment response.
Cell therapy offers a particularly relevant example. Combining genomic analysis with advanced immunophenotyping can help researchers evaluate viral vector performance, identify affected cell populations and better understand therapeutic mechanisms.
This multidisciplinary approach is becoming increasingly important as clinical trials generate more complex biological datasets.
AI and Proteomics: The Next Frontier in Precision Medicine
Looking ahead, MacLean identified AI-driven data integration and advances in proteomics as important developments shaping the future of biomarker research.
With clinical studies generating increasingly large datasets across genomics, flow cytometry and pathology, AI offers opportunities to integrate and interpret information that has traditionally been analysed separately.
MacLean also observed growing interest in proteomic technologies as researchers explore additional approaches to biomarker identification and characterisation.
However, she stressed that the objective is not to prioritise one technology over another, but to determine how different analytical methods can be combined to deliver the greatest value in clinical trials.
Looking Ahead: From Data Generation to Clinical Impact
The next phase of precision medicine will depend not simply on generating more biological data, but on translating that information into robust, clinically meaningful insights.
For MacLean, progress will require stronger integration between analytical platforms, earlier investment in assay quality and standardisation, and more effective use of AI to interpret complex multimodal datasets.
Ultimately, the opportunity lies in connecting scientific innovation with reliable clinical execution, enabling more informed biomarker strategies, improved patient selection and more effective therapeutic development.







